Corcept Therapeutics Incorporated (CORT)

First Trust Advisors LP trimmed its position in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 41.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 537,186 shares of the biotechnology company's stock after selling 387,131 shares during the period. First

Cerity Partners LLC grew its stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) by 21.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 746,593 shares of the biotechnology company's stock after buying an additional 131,799 shares during the quarter. Cerity Partners

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have earned an average rating of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating

Envestnet Asset Management Inc. raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 22.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,847 shares of the biotechnology company's stock after buying an additional 7,077 shares during the quarter.

Aviva PLC trimmed its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,563 shares of the biotechnology company's stock after selling 3,805 shares during the quarter.

CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.

Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean Maduck - President of Endocrinology Joseph K. Belanoff - Co-Founder, President, CEO & Director William Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord Genuity Corp., Research Division David Amsellem - Piper Sandler & Co., Research Division Asim Rana - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2025. Financial Results “The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique acces.

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical.

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to its preference for exclusive partnerships, causing some market confusion. CORT management and sell-side analysts confirm Curant Health is smoothly processing all new prescription growth, ensuring continuity.